AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38578686
Drug: Self-guided lifestyle
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-guided lifestyle intervention (12-week duration, including 1 virtual group session, digital tools, access to self-paced web- and mobile-based content, and 12 weekly health risk text messages)
Trial: 38579297
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of elemental oral iron as ferrous sulfate
Trial: 38579297
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of elemental oral iron as ferrous sulfate
Trial: 38579297
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of elemental oral iron as ferrous sulfate
Trial: 38579297
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of elemental oral iron as ferrous sulfate
Trial: 38579300
Drug: In-hospital intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital intervention (evaluation of inhalation technique and PIF, provision of a written guide, therapeutic education)
Trial: 38579315
Drug: NSAID-based pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID-based pain control (oral acetaminophen and intravenous ketorolac)
Trial: 38580007
Drug: Serum uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum uric acid levels (dose-response analysis)
Trial: 38580350
Drug: Any treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment (conventional or biological antirheumatic treatment)
Trial: 38580355
Drug: Alpha-2 agonists
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-2 agonists (clonidine and dexmedetomidine)
Trial: 38580373
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (pharmacological nutritional hypercaloric products)
Trial: 38580386
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg vedo-800CW
Trial: 38580386
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg vedo-800CW after unlabelled vedolizumab
Trial: 38580386
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg vedo-800CW
Trial: 38580444
Drug: Monthly emailed
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly emailed behavioural 'nudge' messages encouraging compliance with social norms and clinical guidelines around prescribing.
Trial: 38581534
Drug: Eribulin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin and AIs (combined treatment)
Trial: 38581616
Drug: Donanemab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donanemab (700 mg for three doses, then 1400 mg/dose, intravenous every 4 weeks for 72 weeks)
Trial: 38581739
Drug: Psilocybin pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin pulse (10 mg/70 kg, 3 doses, 5 days apart)
Trial: 38581842
Drug: Sitagliptin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin with basal-plus (BP) insulin regimen
Trial: 38581926
Drug: Variable tidal
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable tidal volume (6 ml/kg PBW ± 33% at 5-min intervals)
Trial: 38581926
Drug: Fixed tidal
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed tidal volume (6 ml/kg PBW)
Trial: 38582092
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m²) in group A
Trial: 38582092
Drug: Chemotherapy-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-free treatment with trastuzumab and pertuzumab in group B
Trial: 38582271
Drug: Vonoprazan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan (20 mg twice a day for 3 days, then 20 mg once a day for 28 days)
Trial: 38582271
Drug: High-dose PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PPI (pantoprazole intravenous infusion 8 mg/h for 3 days, then omeprazole 20 mg twice a day for 28 days)
Trial: 38582540
Drug: Placebo (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (chemotherapy only)
Trial: 38582650
Drug: Olaparib plus
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib plus abiraterone (300 mg bid + 1000 mg od)
Trial: 38582650
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus abiraterone (placebo + 1000 mg od)
Trial: 38582713
Drug: Lenvatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib plus Pembrolizumab (L + P)
Trial: 38582934
Drug: Robotic-assisted early
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-assisted early mobilization (20 min, twice daily during the first week in ICU)
Trial: 38583091
Drug: Standard-dose quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose quadrivalent inactivated influenza vaccine
Trial: 38583092
Drug: Plozasiran (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran (10, 25, or 50 mg)
Trial: 38583146
Drug: Simultaneous virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP1-RA
Trial: 38583146
Drug: Education-First (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education-First (2 months of virtual education followed by medication prescription)
Trial: 38583185
Drug: Telephone-based telehealth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based telehealth model for guideline-directed medical therapy initiation and titration.
Trial: 38583289
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg subcutaneously every 4 weeks
Trial: 38583316
Drug: Non-hormonal pessary
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-hormonal pessary applied once daily for the first 7 days and twice a week for the subsequent 31 days
Trial: 38583450
Drug: Stable-dose conventional
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable-dose conventional synthetic DMARDs (n=80)
Trial: 38583450
Drug: Half-dose conventional
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose conventional synthetic DMARDs (n=42)
Trial: 38583450
Drug: Half-dose conventional
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose conventional synthetic DMARDs tapering to withdrawal (n=38)
Trial: 38583455
Drug: Remission induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission induction with high-dose cytarabine (3 g/m²)
Trial: 38583491
Drug: JNJ-3989 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-3989 (200 mg subcutaneously every 4 weeks) + JNJ-6379 (250 mg oral daily) + NA (oral daily)
Trial: 38583540
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg/day for 4 weeks starting on the third day after RFA)
Trial: 38583540
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (historical control, RFA without oral steroids)
Trial: 38583715
Drug: Scheduled analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled analgesia (paracetamol 1 g + ibuprofen 400 mg every 6 hours for the first 24 hours postpartum)
Trial: 38583720
Drug: Radical radiotherapy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiotherapy and local treatment of metastases
Trial: 38583720
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy after radiotherapy
Trial: 38584159
Drug: Quadpill (candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadpill (candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg)
Trial: 38584166
Drug: Personalized therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized therapeutic cancer vaccine (PTCV) GNOS-PV02 coadministered with plasmid-encoded interleukin-12 plus pembrolizumab
Trial: 38584600
Drug: Fuke Qianjin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuke Qianjin capsule, dosage and duration not available
Trial: 38585206
Drug: TAR-200 treatment
RxNorm normalized name: coal tar 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAR-200 treatment (two 7-day or two 21-day dosing cycles)
Trial: 38585206
Drug: TAR-200 treatment
RxNorm normalized name: coal tar 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAR-200 treatment
Trial: 38997620
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg daily for 12 months
Trial: 38586018
Drug: Calorie absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie absorption assessment
Trial: 38586120
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of megestrol acetate (625 mg/5 mL)
Trial: 38586120
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of megestrol acetate (625 mg/5 mL)
Trial: 38586278
Drug: Mandatory twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory twice-weekly evaluations
Trial: 38586278
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care weekly clinical evaluations with ad hoc supplemental evaluations
Trial: 38586479
Drug: High-dose RBT-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose RBT-1 (90 mg SnPP/240 mg FeS)
Trial: 38586479
Drug: Low-dose RBT-1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RBT-1 (45 mg SnPP/240 mg FeS)
Trial: 38586479
Drug: High-dose RBT-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose RBT-1
Trial: 38586479
Drug: Low-dose RBT-1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RBT-1
Trial: 38587033
Drug: LP-PRP injection
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP-PRP injection during surgery (5-mL dose)
Trial: 38587079
Drug: 10E8VLS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10E8VLS (5 mg/kg)
Trial: 38587079
Drug: 10E8VLS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10E8VLS and VRC07-523LS (5 mg/kg each)
Trial: 39217567
Drug: Semaglutide (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (2.4 mg once weekly)
Trial: 38587249
Drug: 80-mg olezarsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-mg olezarsen
Trial: 38587249
Drug: 50-mg olezarsen
RxNorm normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg olezarsen
Trial: 38587241
Drug: Beta-blocker treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker treatment (metoprolol or bisoprolol)
Trial: 39221651
Drug: CSL112 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (6 g, four weekly infusions)
Trial: 38587276
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (E2) gel + ADT
Trial: 38587329
Drug: Customizable sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customizable sequential digital cognitive aid (DCA) with ILCOR algorithm poster displayed on the wall
Trial: 38587333
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (control)
Trial: 38587380
Drug: Dolutegravir/lamivudine FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir/lamivudine FDC (50 mg dolutegravir and 300 mg lamivudine)
Trial: 38587645
Drug: Toludesvenlafaxine hydrochloride
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toludesvenlafaxine hydrochloride 9 mg/kg (i.v.) followed by 3 mg/kg infusion via minipump
Trial: 38587645
Drug: Toludesvenlafaxine hydrochloride
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toludesvenlafaxine hydrochloride 32 mg/kg oral administration
Trial: 38587643
Drug: trastuzumab-pertuzumab and
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab-pertuzumab and chemotherapy de-escalation
Trial: 38587822
Drug: Zerlasiran 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerlasiran 300 mg
Trial: 38587822
Drug: Zerlasiran 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerlasiran 600 mg
Trial: 38587822
Drug: Zerlasiran 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerlasiran 200 mg (two doses)
Trial: 38587822
Drug: Zerlasiran 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerlasiran 300 mg (two doses)
Trial: 38587822
Drug: Zerlasiran 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerlasiran 450 mg (two doses)
Trial: 38587852
Drug: Naked-eye 3-dimensional
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naked-eye 3-dimensional vision training (NVT) for 20 minutes daily
Trial: 38587881
Drug: Individual psychotherapy
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual psychotherapy (treatment as usual, no postsession questionnaires)
Trial: 38588480
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg methylprednisolone i.v./d plus erythropoietin (33,000 IU/d) for 3 days
Trial: 38588480
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg methylprednisolone i.v./d plus placebo (saline solution) for 3 days
Trial: 38588588
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm (placebo antibiotic/placebo microbiome modulation + nivolumab)
Trial: 38588682
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2)
Trial: 38588696
Drug: Neoadjuvant olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant olaparib with chemotherapy
Trial: 38589574
Drug: Concurrent inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent inhibition of oncogenic and wild-type RAS-GTP
Trial: 38589856
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with gemcitabine, cisplatin, and nabpaclitaxel (GAP)
Trial: 38589856
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with GAP
Trial: 38589926
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX), 2-4 cycles before surgery and 4-6 cycles after surgery.
Trial: 38589926
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX), 8 cycles after upfront surgery.
Trial: 38589926
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX).
Trial: 38589926
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX).
Trial: 38590283
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment using the heparin-bonded Viabahn endoprosthesis
Trial: 38590716
Drug: Consolidation chemoradiation
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemoradiation (CTRT) with concurrent capecitabine at 1250 mg/m2
Trial: 38590831
Drug: 15g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15g of specific collagen peptides (SCP) daily
Trial: 38591260
Drug: Mavacamten, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten, 5 mg once daily with individualized dose titration at week 6
Trial: 38591748
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase within 4.5 hours of symptom onset
Trial: 38591808
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose at the extraction site
Trial: 38591811
Drug: Mibavademab (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibavademab (0.3, 1.0, 3.0, 10, and 30 mg/kg i.v. or 300 and 600 mg subcutaneous)
Trial: 38591811
Drug: Mibavademab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibavademab (15 mg/kg i.v. loading dose and 10 mg/kg i.v. at weeks 3, 6, and 9)
Trial: 38591829
Drug: iFightDepression-SURVIVE (iFD-S)
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iFightDepression-SURVIVE (iFD-S) with treatment as usual (TAU)
Trial: 38591997
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of coronary artery calcium score (Ca-score) and high-sensitivity cardiac troponin T (hs-cTnT)
Trial: 38593233
Drug: Posoleucel infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posoleucel infusion initiated within 15 to 49 days of allo-HCT, subsequently every 14 days for up to 7 doses.
Trial: 38593233
Drug: Posoleucel infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posoleucel infusion
Trial: 38593241
Drug: Pegcetacoplan therapy
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegcetacoplan therapy
Trial: 38593249
Drug: Nicotinamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1 g/day)
Trial: 38593348
Drug: RMC-6236 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-6236 at 300 mg daily
Trial: 38593348
Drug: RMC-6236 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-6236 at 100 mg and 300 mg daily
Trial: 38593512
Drug: Adavosertib 250
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 250 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Trial: 38593512
Drug: Adavosertib 200
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 200 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Trial: 38593947
Drug: Inclisiran (284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (284 mg at days 0, 90, and 270) plus usual care
Trial: 38594150
Drug: Renal Replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal Replacement Therapy (RRT)
Trial: 38594150
Drug: Norepinephrine/Epinephrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine/Epinephrine treatment
Trial: 38594245
Drug: WU-04 (non-covalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WU-04 (non-covalent inhibitor)
Trial: 38594245
Drug: Ensitrelvir and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir and nirmatrelvir (clinically used inhibitors)
Trial: 38594435
Drug: Increasing adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Increasing adalimumab (ADA) dose intervals to 3 and then to 4 weeks.
Trial: 38594435
Drug: Increasing adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Increasing adalimumab (ADA) dose intervals.